Two Proprietary Innovation Platforms
Driven by innovation, JW Therapeutics continues to advance foundational technologies and build proprietary platforms that evolve through continuous innovation. By accelerating the translation of scientific breakthroughs into clinical value, we are committed to delivering safer, more effective, and more accessible cell therapies to patients worldwide.
An End-to-End Platform for Next-Generation CAR-T Development and Clinical Translation
Jweave is JW Therapeutics' proprietary end-to-end CAR-T technology platform, spanning every critical stage of development and manufacturing—from gene of interest (GOI) discovery and vector design to process development, viral vector manufacturing, cell engineering, cell expansion, and quality control (QC) release.
Built on a foundation of standardization, modularity, and automation, the platform enables the efficient development and robust manufacturing of multi-target and armored CAR-T therapies. By integrating R&D efficiency, process excellence, and scalable manufacturing, Jweave™ accelerates the translation of next-generation cell therapies and strengthens JW Therapeutics' global innovation capabilities.
A Proprietary Lentiviral Vector Platform with Global Partnership Potential
JW Vectails Lentiviral System is JW Therapeutics' proprietary suspension-based lentiviral vector platform, designed to address one of the most critical aspects of cell therapy development—gene delivery and vector manufacturing. The platform integrates comprehensive capabilities across process development, scalable manufacturing, and quality control to support reliable and efficient lentiviral vector production.
The platform supports the development and manufacturing of JW Therapeutics' marketed CAR-T therapy and next-generation pipeline programs. Through technology licensing collaborations with leading global cell therapy companies, it has also demonstrated its potential in process maturity, technology transfer, and industrial scalability. Looking ahead, the platform is well positioned to support next-generation innovations, including engineered CAR-T therapies, armored CAR-T therapies, and in vivo gene delivery applications.
Platform Value & Impact
Advancing Next-Generation CAR-T Innovation
- Advancing an armored CAR-T program into clinical development.
- Building a proprietary in vivo CAR-T platform powered by advanced lentiviral vector technologies.
Breaking Down Technological Barriers to Expand Globally
- Successfully developed domestically produced lentiviral vectors and achieved the localization of key materials.
- Exporting technology licenses to the US market showcases China's innovative strength in cell therapy.
A Comprehensive and Diversified R&D Pipeline
- Advancing a broad pipeline spanning hematologic malignancies, solid tumors, and autoimmune diseases.
- Addressing significant unmet medical needs through continuous innovation.